Abstract
BACKGROUND:
The p.Arg14del variant of the phospholamban (PLN) gene causes cardiomyopathy, leading to severe heart failure (HF). Calcium handling defects and perinuclear PLN aggregation have both been suggested as pathological drivers of this disease. Dwarf open reading frame (DWORF) has been shown to counteract PLN regulatory calcium handling function in the sarco/endoplasmic reticulum (S/ER). Here we investigated the potential disease modulating action of DWORF in this cardiomyopathy and its effects on calcium handling and PLN aggregation.
METHODS:
We studied a PLN-R14del mouse model, which develops cardiomyopathy with similar characteristics as human patients, and explored whether cardiac DWORF overexpression could delay cardiac deterioration. To this end, homozygous PLN-R14del (R14Δ/Δ) mice carrying the DWORF transgene (R14Δ/ΔDWORFTg) were used.
RESULTS:
DWORF expression was suppressed in hearts of R14Δ/Δ mice with severe HF. Restoration of DWORF expression in R14Δ/Δ mice delayed cardiac fibrosis and HF, and increased life span more than 2-fold (from 8 to 18 weeks). DWORF accelerated SR calcium re-uptake and relaxation in isolated cardiomyocytes with wildtype PLN, but in R14Δ/Δ cardiomyocytes SR calcium re-uptake and relaxation were already enhanced and no differences were detected between R14Δ/Δ and R14Δ/ΔDWORFTg. Rather, DWORF overexpression delayed the appearance and formation of large pathogenic perinuclear PLN clusters. Careful examination revealed co-localization of SR markers with these PLN clusters in both R14Δ/Δ mice and human p.Arg14del PLN heart tissue and hence these previously termed aggregates are comprised of abnormal organized S/ER. This abnormal S/ER organization in PLN-R14del cardiomyopathy contributes to cardiomyocyte cell loss and replacement fibrosis, consequently resulting in cardiac dysfunction.
CONCLUSIONS:
Disorganized S/ER is a major characteristic of PLN-R14del cardiomyopathy in humans and mice, and results in cardiomyocyte death. DWORF overexpression delayed PLN-R14del cardiomyopathy progression and extended life span in R14Δ/Δ mice, by reducing abnormal S/ER clusters.
Keywords: DWORF, cardiomyopathy, phospholamban, p.Arg14del, sarcoplasmic reticulum
Keywords: Basic Science Research, Calcium Cycling/Excitation-Contraction Coupling, Translational Studies, Pathophysiology
INTRODUCTION
A number of pathogenic mutations in the gene coding for phospholamban (PLN) have been identified that cause cardiomyopathy. The p.Arg14del pathogenic variant is the best described and most prevalent variant, and may cause dilated cardiomyopathy (DCM) or arrhythmogenic cardiomyopathy (ACM), often resulting in severe heart failure (HF) with characteristic perinuclear PLN aggregates 1,2. So far, no specific treatment for this cardiomyopathy is available and heart transplantation often is needed as a last resort.
PLN is a small cardiac-specific protein that localizes to the sarcoplasmic reticulum (SR) membrane, where it negatively regulates the re-uptake of cytosolic calcium ions (Ca2+) into the SR via its interaction with the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 3. Calcium handling studies have shown different effects of PLN-R14del on SERCA regulation and the precise contribution of dysfunctional SERCA regulation in the pathology of this disease is still under debate 4–8. Additionally, functions of PLN have been attributed to nuclear and mitochondrial mechanisms 9,10, suggesting more complex PLN interactions and function. A recent study using human induced pluripotent stem cell (hiPSC)-derived cardiac tissues suggested impairment of the endoplasmic reticulum (ER)/mitochondria compartment as a novel disease mechanism underlying PLN-R14del cardiomyopathy 10. Interestingly, human PLN-R14del cardiomyopathy is characterized by the presence of dense perinuclear PLN protein aggregates in cardiomyocytes 11. Furthermore, in a mouse model of PLN-R14del cardiomyopathy, clustered perinuclear PLN protein was identified and was consistently found to be the first pathological sign, preceding the onset of cardiac dysfunction, suggesting a causal role 12,13. So far, the exact nature of the perinuclear PLN aggregates in PLN-R14del cardiomyopathy is unknown, but the strong association with disease development warrants further investigations.
A recently discovered SR localized micropeptide, termed dwarf open reading frame (DWORF), with a function opposite to PLN, was strongly down-regulated in humans and mice with HF 14–16. Using a transgenic mouse line, DWORF overexpression was shown to improve SERCA mediated calcium re-uptake and prevent HF in the muscle LIM protein knock-out (MLP-KO) DCM mouse model 17. In addition, DWORF overexpression improved ventricular function and reduced cardiac dilation in a mouse model of myocardial infarction (MI) 18. These studies have thus shown that DWORF overexpression is cardioprotective in HF from genetic but also common etiology, most likely via enhanced calcium re-uptake. Whether DWORF affords cardioprotection in PLN-R14del cardiomyopathy, with its characteristic dense perinuclear PLN clusters, is unknown.
A mouse model that recapitulates the human PLN-R14del pathological phenotype has been described 12. Mice harboring the heterozygous mutation develop disease characteristics at around 18 months of age, which is similar to what clinically is observed in humans where age of onset often is around 40–50 years of age. Mice harboring both pathogenic PLN-R14del alleles (homozygous, R14Δ/Δ) showed an enhanced and accelerated phenotype developing in 4–8 weeks, while standard HF treatments could not attenuate disease progress, again in accordance with clinical observations 12.
Here, we investigated the effect of DWORF overexpression in PLN-R14del cardiomyopathy. In particular, DWORFTg mice were crossbred with PLN-R14Δ/Δ mice to generate R14Δ/ΔDWORFTg mice. We found that overexpression of DWORF in PLN-R14Δ/Δ mice reduced PLN-R14del-induced S/ER cluster formation, improved cardiac function and extended life span.
METHODS
Data Availability.
The data, methods, and study materials used to conduct the research are available from the corresponding authors on reasonable request. Expanded Methods are available in the Supplemental Material, also please see the Major Resources Table in the Supplemental Materials.
Animals
Animal studies were approved by the Central Committee of Animal experiments (CCD, license number AVD1050020199105) and the animal ethical committee of the University of Groningen (permit numbers IVD199105-01-003, IVD199105-01-010 and IVD199105-01-022 for the current study, IVD1583-02-001 for DWORF gene expression in 3- to 7-week-old R14Δ/Δ mice and DEC6827A, DEC6920A and IVD16487-03-01 for the samples we used from the study from Du et al.19) and conformed with the guidelines from the Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes, and reported following the ARRIVE guidelines 20.
Study design
To determine the effect of DWORF overexpression on the development of PLN-R14del cardiomyopathy, the DWORFTg mice were crossed with the PLN-R14Δ/Δ mouse model (R14Δ/ΔDWORFTg). Mice were assigned to the experimental groups by their genotype. The life span of R14Δ/Δ mice with and without DWORF overexpression (male and female, in total n=7–9 per group) was determined. Furthermore, cardiac function of these mice and their wildtype (WT, transgene-negative) littermates was evaluated using echocardiography at 4, 6, 10, 14 and 18 weeks of age. In addition, electrocardiography (ECG) and several histological and molecular analyses were performed at 3, 5, 7 and 18 weeks of age (both male and female, mice of each genotype were randomly assigned to the different experimental time points, per group n=3, 8, 10 and 8 respectively). R14Δ/ΔDWORFTg mice that reached the humane endpoint (which occurred between 17 and 20 weeks of age) and their 22-week-old WT controls, will be referred to as 18 weeks of age.
Echocardiography
Two-dimensional transthoracic echocardiography measurements were performed using the Vevo 3100 system with a 40-MHz MXX550D linear array transducer (FUJIFILM VisualSonics, Canada) as described previously 21. During imaging, mice were anaesthetized with a mixture of oxygen and isoflurane (2.5%). Cardiac dimensional and functional parameters were determined using Vevo LAB software (version 3.2.6; FUJIFILM VisualSonics). Data acquisition and analysis were conducted in accordance with the recommendations of the European Society of Cardiology (ESC) Working Group on Myocardial Function 22 and were performed in a blinded fashion.
Surface electrocardiography
Lead II configuration ECG recordings were acquired on anesthetized mice (2.5% isoflurane mixed with oxygen), by a previously reported procedure 12. Subdermal needle electrodes were connected to a PowerLab 8/30 data acquisition device (model ML870; ADInstruments, New-Zealand) and an animal Bio Amp biological potential amplifier (model ML136; ADInstruments), which transferred recordings to LabChart Pro software (version 8; ADInstruments). The ECG Analysis module was used for data analysis.
Histological analysis
Heart tissue was fixed overnight in 4% buffered formaldehyde solution (4% formalin; Klinipath, the Netherlands). Afterwards, tissues were dehydrated using an automated system (Leica TP1020, Leica Microsystems, Germany), embedded in paraffin (Klinipath) and cut into 4-μm thick sections. Slides were deparaffinized before proceeding with the subsequent staining protocol. Staining protocols are available in the Supplemental Material and the antibodies used are presented in Table S1.
Western blot analysis
Radioimmunoprecipitation assay (RIPA) lysis buffer was used to isolate proteins from snap-frozen LV tissue as described previously 12. Quantification was performed using ImageJ software (National Institutes of Health) 23 and the measurements of the protein of interest were corrected for the measured total amount of loaded protein that was determined using the Revert 700 Total Protein Stain (LI-COR Biosciences, NE, USA). The calculated values were presented as a fold change compared to the age-matched control group. The primary and secondary antibodies that were used are presented in Table S3.
Calcium transient and contraction measurements in isolated adult mouse cardiomyocytes
Cardiomyocytes were isolated from WT, R14Δ/Δ and R14Δ/ΔDWORFTg mice at 3 weeks or 6 weeks of age (n=4 per genotype) using the protocol of Ackers-Johnson et al. 24. An IonOptix Calcium and Contractility System (IonOptix corporation, MA, USA) was used to measure calcium transients and video-based sarcomere length (SL) in Fura-2 loaded cardiomyocytes under pacing conditions (IonOptix MyoPacer; 2 Hz, 4 ms pulse duration, 20 V) at 37°C. Calcium and contractility data were analyzed using CytoSolver, a cloud-based analysis program of IonOptix.
Electron microscopy
Electron microscopy (EM) with PLN-quantum dot immunolabeling was performed as reported previously 25,26.
Statistical analyses
All data are presented as means ± standard errors of the mean (SEM), with the exception of calcium transient and contraction data that are presented as truncated violin plots (median and quartiles are indicated by lines). Nonparametric tests were performed because of small group sizes. Therefore, the Mann-Whitney U test was performed for comparisons between two groups and the Kruskal-Wallis test followed by Dunn’s post hoc test for multi-group comparisons. For statistical analysis of survival curves, a log-rank test was performed. Since individual cardiomyocytes instead of individual animals were plotted for calcium transient and contraction data, a hierarchical cluster analysis using customized R software (version 4.3.1) was applied according to the method described by Sikkel et al. 27, after log-transformation of the data because of non-normal distribution. All other statistical analyses were performed using GraphPad Prism (version 8.4.2, GraphPad Software, MA, USA). P-values < 0.05 were considered statistically significant. Additional details on all statistical tests performed can be found in a supplemental statistical report.
RESULTS
DWORF overexpression extended life span and improved cardiac function in R14Δ/Δ mice
DWORF has been shown to be downregulated in HF in both mice and humans 14,17. We confirmed downregulation of cardiac DWORF gene expression in our PLN-R14del cardiomyopathy mouse model (Figure S1A). At end-stage disease, DWORF gene expression levels in PLN-R14del mice were significantly lower than in mice with myocardial ischemia reperfusion (I/R) injury and in mice that underwent myocardial infarction (MI) (Figure S1B). Since DWORF and PLN have been reported to have opposite functions, we investigated whether elevated DWORF levels could have beneficial effects against PLN-R14del cardiomyopathy development. To this aim, DWORFTg and PLN-R14Δ/Δ mice were crossed (R14Δ/ΔDWORFTg) and an elevated DWORF protein level in the R14Δ/ΔDWORFTg strain was confirmed by Western blot analysis (Figure S1C,D). To determine the effect of DWORF overexpression on the development of PLN-R14del cardiomyopathy, cardiac function and cardiac histological and molecular changes were evaluated over time and life span was determined, as outlined in Figure 1A.
A striking extension of life span was achieved by DWORF overexpression in PLN-R14Δ/Δ mice. While R14Δ/Δ mice have a limited life span of ~8 weeks, this was substantially prolonged to 17–20 weeks by DWORF overexpression (R14Δ/ΔDWORFTg) (Figure 1B). Moreover, at 6 weeks of age, cardiac function (left ventricular ejection fraction [LVEF]) of R14Δ/Δ mice was already severely impaired (LVEF<35%), whereas cardiac function of R14Δ/ΔDWORFTg mice was still preserved (LVEF>55%) and comparable to WT (Figure 1C,D). At about 10 weeks of age, cardiac dysfunction was detected in the R14Δ/ΔDWORFTg mice and at 14 weeks the LVEF was as severely impaired as in the 6 weeks R14Δ/Δ group. Other parameters of PLN cardiomyopathy were also attenuated by DWORF overexpression, including the end-systolic diameter (Figure 1E), a measure of cardiac dilatation during contraction. The end-diastolic diameter did not significantly change in R14Δ/Δ mice and in R14Δ/ΔDWORFTg mice at 6 weeks, but it increased in R14Δ/ΔDWORFTg mice starting at 14 weeks of age (Figure 1F). Since low-voltage ECGs are a hallmark of PLN-R14del cardiomyopathy in patients, the ECG potential was quantified by the peak-to-peak amplitude at different time points in this study. At 7 weeks of age, ECG peak-to-peak amplitude was significantly reduced in the R14Δ/Δ group (0.48±0.04 mV, p<0.05 vs. WT 1.41±0.27 mV), whereas ECG potentials were preserved in R14Δ/ΔDWORFTg mice (1.06±0.07 mV) (Figure 1G,H). At 18 weeks of age, the amplitude of the R14Δ/ΔDWORFTg group was decreased to 0.42±0.12 mV as well. The quantification of P, R and S amplitudes is displayed in the Supplemental Material (Figure S2). Together these results indicate that DWORF overexpression delayed cardiac impairment in R14Δ/Δ mice, thereby extending the life span of these mice.
DWORF overexpression delayed cardiac remodeling in R14Δ/Δ mice
The positive effects of DWORF on the development of HF were also validated at the molecular level. The well-documented increases in gene expression of the HF marker Nppa (atrial natriuretic peptide [ANP]) and the ratio Myh7/Myh6 (Myosin Heavy Chain 7, encoding β-MHC; Myosin Heavy Chain 6, encoding α-MHC) in R14Δ/Δ mice, was significantly reduced by DWORF overexpression at both 5 and 7 weeks of age (Figure 2A,B). For both Nppa and the ratio Myh7/Myh6, an expression level comparable to 7-week-old R14Δ/Δ mice was reached in R14Δ/ΔDWORFTg mice at 18 weeks of age. Moreover, elevation of gene expression of the fibrotic markers Col1a1 (collagen type I alpha 1 chain) and Lgals3 (Galectin-3) was delayed by overexpression of DWORF in PLN-R14Δ/Δ mice (Figure 2C,D).
Consistent with these findings, histological analyses revealed that fibrosis occurred significantly slower in R14Δ/ΔDWORFTg mice as compared to R14Δ/Δ mice (2.6±0.4% vs. 12.5±1.0% at age 7 weeks, p<0.05; WT 1.2±0.2%) (Figure 2E,F). At 18 weeks of age, cardiac fibrosis was elevated in the R14Δ/ΔDWORFTg group as well (12.1±0.4%, p<0.05 vs. WT).
DWORF overexpression did not alter calcium re-uptake in R14Δ/Δ mice
To investigate calcium handling and sarcomere contraction and relaxation, mouse cardiomyocytes were isolated at 3 weeks of age, before disease onset. Calcium transient investigations (Tau, Time to 80% decay of calcium peak, T80, and relaxation velocity) showed accelerated relaxation in both R14Δ/Δ and R14Δ/ΔDWORFTg compared to WT, and no difference between R14Δ/Δ and R14Δ/ΔDWORFTg (Figure 3A,B). In agreement with previous data14, DWORFTg in a wildtype PLN background significantly decreased Tau (Figure S3A,B), but DWORF overexpression had no additional effect in R14Δ/Δ cardiomyocytes, because of the already low Tau value in R14Δ/Δ. No significant differences in calcium amplitudes were observed between cardiomyocytes from the different genotypes (Figure 3A and Table S4). Consistent with calcium observations, sarcomere relaxation velocity was significantly enhanced in both 3-week-old R14Δ/Δ and R14Δ/ΔDWORFTg derived cardiomyocytes compared to WT, and there was no difference between R14Δ/Δ and R14Δ/ΔDWORFTg in sarcomere relaxation time and relaxation velocity (Figure 3C,D). Beneficial effects by DWORF overexpression could also not be explained by an increase in sarcomere fractional shortening (FS) (Figure S3C,D) since there was no significant difference in FS between R14Δ/ΔDWORFTg and R14Δ/Δ cardiomyocytes (Figure 3C,D). β-Adrenergic stimulation with isoproterenol (ISO) enhanced contraction and relaxation in all genotypes, but had a reduced effect on relaxation parameters in R14Δ/ΔDWORFTg and R14Δ/Δ cardiomyocytes, which is in accordance with the improved baseline values in these genotypes (Figure 3A–D). Cardiomyocytes isolated at 6 weeks of age, when disease is already present, were also investigated. Cardiomyocyte isolation was more challenging for the 6 week R14Δ/Δ hearts, and yields of viable cardiomyocytes were consistently lower (about 8 fold lower as compared to WT). Data from these apparent more vulnerable cardiomyocytes, which at this age also have become hypertrophic (Figure S4A), should therefore be interpreted with caution. Nevertheless, even though sarcomere data depict reduced quality of the 6-week-old R14Δ/Δ isolated cardiomyocytes, calcium transients at this age are similar to the findings at 3-weeks-of age (Figure S4B–E). Together, the above results demonstrate that calcium re-uptake is accelerated in R14Δ/Δ mice and indicate that the mechanism by which DWORF inhibits disease progression R14Δ/Δ mice is unrelated to a change in calcium handling.
DWORF overexpression inhibited the formation of characteristic PLN aggregates in R14Δ/Δ mice
Since hearts of PLN-R14del patients and R14Δ/Δ mice display characteristic dense perinuclear PLN localization, the effect of DWORF on this phenomenon was evaluated. While perinuclear PLN accumulation was present in almost all cardiomyocytes of R14Δ/Δ mice at 7 weeks of age, R14Δ/ΔDWORFTg mice had only a few PLN aggregate positive cardiomyocytes (Figure 4A,B). Strikingly, even at 18 weeks of age only a limited number of cardiomyocytes showed this characteristic PLN mislocalization. This demonstrates that DWORF overexpression is associated with less perinuclear PLN mislocalization. In correspondence with previous data 12,28, there was a trend towards decreased PLN protein levels in 7-week-old R14Δ/Δ mice compared to WT (p=0.07), and the slower electrophoretic PLN phosphorylated forms were absent in R14Δ/Δ mice (Figure 4C,D). PLN protein levels were comparable between R14Δ/Δ and R14Δ/ΔDWORFTg mice at both 7 and 18 weeks of age (Figure 4C,D), even though fewer perinuclear PLN clusters were present in R14Δ/ΔDWORFTg mice (Figure 4A,B). Thus, the difference in PLN accumulation was not a result of altered PLN protein expression. Together this indicates that perinuclear PLN accumulation is a key pathological process in PLN-R14del cardiomyopathy and its reduction can delay disease development.
Dense PLN perinuclear structures are comprised of mislocalized S/ER
Despite the pathological relevance of PLN accumulation in PLN-R14del cardiomyopathy, little is known about the composition of these perinuclear PLN clusters. To obtain more information about the ultrastructure of this clustered PLN, electron microscopy (EM) was performed on LV tissue from 7-week-old R14Δ/Δ mice, 18-week-old R14Δ/ΔDWORFTg mice and WT controls. Using quantum dot labeling of an anti-PLN antibody, PLN clusters were visualized in the EM samples.
In R14Δ/Δ mice, highly dense clusters of labeled PLN were mainly present in the perinuclear region (Figure 5A, PLN clusters outlined in red, nucleus outlined in blue), which corresponds with the initial description of perinuclear localization of PLN aggregates in PLN-R14del patient material 11,29. Importantly, the clustered PLN labeling was present in large membrane-like structures (Figure 5B). These structures were also present in 18-week-old R14Δ/ΔDWORFTg mice (Figure 5C,D), but were not as abundant as compared to R14Δ/Δ mice, in agreement with fluorescent imaging (Figure 4A,B). In WT hearts, no PLN clusters were detected, but labeled PLN was distributed throughout the cell and localization to organized sarco/endoplasmic reticulum (S/ER) structures was observed (Figure 5E,F). The clustered membrane like structures in R14Δ/Δ cardiac tissue did not correspond with vesicles like autophagosomes, which have double layer membranes, or lysosomes, which are spherical vesicles. Since PLN is a transmembrane protein anchored in the SR membrane, these large membrane structures could be disorganized clusters of the S/ER membrane.
To investigate the organization of the S/ER in cardiomyocytes from R14Δ/Δ mice, immunofluorescence (IF) microscopy was performed on LV tissue from R14Δ/Δ and WT mice to visualize PLN together with other S/ER resident proteins. In contrast to the equal distribution throughout the cardiomyocytes observed in WT mice (Figure S5), clustering of the longitudinal tubular SR resident proteins SERCA2, histidine-rich calcium-binding protein (HRC) and calnexin was observed in cardiac tissue from R14Δ/Δ mice (Figure 6). Moreover, these SR resident proteins co-localized with PLN at the perinuclear clusters (Figure 6). The structural ER protein atlastin-3 (ATL3) clustered and co-localized with the PLN clusters as well (Figure 6). In contrast, the sarcomere protein troponin and mitochondrial protein Tom20 were distributed throughout the cell, as in WT mice (Figure S5), and did not co-localize with the PLN clusters in R14Δ/Δ mice (Figure 6). Although fewer clusters were present at 3 weeks of age, when present, SERCA2, HRC, calnexin and ATL3 clustered and co-localized with PLN in R14Δ/Δ mice, while troponin and Tom20 did not and comparable results with more clusters were observed at 5 weeks of age (Figure S6, S7). Similarly, in 18-week-old R14Δ/ΔDWORFTg mice, cardiomyocytes that contained large PLN clusters showed co-localization of SERCA2, HRC, calnexin and ATL3 and with PLN, whereas troponin and Tom20 did not co-localize (Figure S8). These data indicate that more cardiomyocytes develop an abnormal S/ER structure in R14Δ/Δ mice with age and this process is delayed in R14Δ/ΔDWORFTg mice.
To corroborate this finding, we investigated the localization of these SR proteins in cardiac tissue from PLN-R14del human patients and non-PLN-R14del DCM patients. Perinuclear PLN localization could be observed in some cardiomyocytes in PLN-R14del patient-derived heart tissue, as described previously 11. Importantly, SERCA2, HRC, calnexin and ATL3 all colocalized with these PLN clusters in these patient samples (Figure S9), confirming our observations in mice. In non-PLN-R14del DCM patient-derived cardiac tissue, perinuclear PLN clusters were not observed, and S/ER markers showed a normal distribution in all cardiomyocytes (Figure S10). Taken together, these data confirm perinuclear PLN clustering as a key characteristic of PLN cardiomyopathy and show that these previously identified PLN aggregates are comprised of disorganized S/ER and DWORF overexpression can delay this disorganization.
DWORF overexpression delays S/ER disorganization and cell death by restraining PLN cluster size
Closer investigation of abnormal PLN localization revealed that adjacent to cells with large PLN clusters, about 80% of all cardiomyocytes of 18-week-old R14Δ/ΔDWORFTg mice showed the presence of small sized PLN speckles (Figure S11, some PLN speckles are indicated by white arrowheads and Figure S12 for quantification). These PLN speckles could also be observed in about 30% of the cardiomyocytes in 3-week-old R14Δ/Δ mice, often located next to some cells with larger clusters, suggesting that these speckles represent an initial stage that progresses into larger clusters (Figure S11,S12). In 7-week-old R14Δ/ΔDWORFTg mice, these speckles were much less prevalent compared to 18-week-old R14Δ/ΔDWORFTg mice (only in about 30% of all cardiomyocytes), indicating that this phenomenon occurs at a slower rate in the presence of DWORF and/or develop less frequently into larger clusters (Figure S11,S12).
Although we currently do not understand how DWORF interferes with these processes, we believe that PLN clustering and SR disorganization have major consequences for cardiomyocyte cell viability. Severe accumulation of the stress inducible protein, p62, was observed within cardiomyocytes that contain large PLN clusters (Figure 7A). When quantified, R14Δ/Δ mice had a significantly higher count of p62-positive cardiomyocytes compared to R14Δ/ΔDWORFTg mice (Figure S13). About 10% of the p62-positive cardiomyocytes had p62 accumulation throughout the entire cell together with a strongly reduced signal for the troponin protein, which suggest cardiomyocyte death, most likely by necrosis (Figure 7B, Figure S13B). In vivo Evans Blue staining confirmed the presence of necrotic cardiomyocytes in R14Δ/Δ mice (Figure 7C,D). Consistent with these findings, plasma cardiac troponin levels were strongly elevated in 6-week-old R14Δ/Δ mice while skeletal troponin levels remained low, indicative of troponin leakage from the heart (Figure 7E,F). Moreover, plasma cardiac troponin levels were lower in R14Δ/ΔDWORFTg mice compared to R14Δ/Δ mice (Figure 7E,F). The extensive increase in extracellular matrix in 7 weeks R14Δ/Δ mice and 18 weeks R14Δ/ΔDWORFTg (Figure 2) therefore most likely reflects replacement fibrosis, which is in agreement with observations in human PLN-R14del cardiomyopathy hearts 30. Since large PLN-R14del cluster formation is less prominent in R14Δ/ΔDWORFTg mice, the delayed cardiac dysfunction and decreased fibrosis can be explained by a reduced rate of cardiomyocyte cell loss in the hearts of R14Δ/ΔDWORFTg mice.
DISCUSSION
In this study, we demonstrate that DWORF expression can substantially extend life span of mice with PLN-R14del cardiomyopathy. DWORF is substantially reduced in heart failure and restoration of DWORF levels by crossbreeding DWORFTg mice with R14Δ/Δ mice, delayed cardiac dysfunction and fibrosis in these mice. This cardioprotective effect could not be attributed to the role of DWORF in calcium handling. Instead, we provide evidence that characteristic PLN aggregates present in PLN-R14del disease, are comprised of harmful perinuclear clustered S/ER and DWORF has an inhibitory effect on this S/ER disorganization, suggesting a novel cardioprotective role of DWORF in PLN-R14del cardiomyopathy.
We show for the first time that the previously termed perinuclear PLN aggregates, observed in both patients and mice with PLN-R14del cardiomyopathy, are not only composed of PLN protein, but are comprised of aberrantly clustered cardiac S/ER. Using electron microscopy, we revealed perinuclear localized PLN-dense membrane clusters in hearts of R14Δ/Δ mice. Further investigations showed that other S/ER markers, including SERCA2, calnexin, HRC and ATL3, all colocalized with PLN in these membrane clusters in both R14Δ/Δ mouse and PLN-R14del human patient samples. These findings provide clear evidence that in both in mouse and men, PLN-R14del-induced S/ER disorganization is a major characteristic of PLN-R14del cardiomyopathy. So far, the mechanistic aspects of this abnormal S/ER clustering remain elusive. Further investigations will be needed to investigate whether this process involves abnormal PLN-R14del membrane interactions and/or PLN aggregation and complex formation with other proteins in the SR membrane.
In addition to the occurrence of abnormal perinuclear PLN clusters in cardiomyocytes before the onset of cardiac dysfunction 13, our data indicates that cluster formation involves a sequence of events. At an early stage, when the majority of both PLN and S/ER distribution is still normal, the first PLN speckles can be observed in cardiomyocytes. At a later stage, these speckles formed larger PLN clusters and caused severe disorganization of the S/ER. Concurrently, p62 accumulation was observed in about half of the cardiomyocytes with large PLN clusters. Importantly, in about 10% of the cardiomyocytes with p62 cluster formation troponin was strongly reduced, which was accompanied by an increase in plasma troponin levels, which collectively indicates necrotic death of these cardiomyocytes. These results were further confirmed by injection of Evans Blue, a previously described necrotic cell death marker 31, and are again in line with the high vulnerability of these cardiomyocytes during isolation. This also explains the excessive replacement fibrosis in these hearts and concomitant development of hypertrophy in the remaining cardiomyocytes and is in congruence with the cell death-fibrosis phenomenon in HF 32. Importantly, in PLN-R14del mutation carriers fibrosis is an early feature which can already be observed in carriers that still have a preserved LVEF 33. Thus, although the exact molecular processes require further investigations, our observations indicate that abnormal perinuclear S/ER cluster formation is an early phenomenon that drives a sequence of pathological processes resulting in PLN-R14del cardiomyopathy.
Interestingly, DWORF overexpression inhibited the presence of large perinuclear PLN clusters with severe S/ER disorganization in R14Δ/Δ mice. At 3 weeks of age the majority of the R14Δ/ΔDWORFTg cardiomyocytes showed normal PLN distribution and at 18 weeks of age the majority of the R14Δ/ΔDWORFTg cardiomyocytes have PLN speckles. By restraining PLN cluster size and inhibiting the formation of large perinuclear PLN clusters, that are associated with cardiomyocyte death, DWORF overexpression could delay disease development in R14Δ/Δ mice. Currently, we do not know how DWORF mediates PLN cluster size, but since SERCA is present in these clusters as well it may still involve some form of competitive SERCA interactions. The knowledge about the regulation and associations of PLN and other micropeptides, like DWORF, in biological membranes is still limited, but sophisticated technologies like electron paramagnetic resonance spectroscopy might provide answers to this underlying complexity 34. Other mechanisms, like control of dynamic localization via Neprilysin mediated changes in oligomerization states, as shown for Drosophila Sarcolamban should not be excluded, although our results currently do not point into this direction 35. Unfortunately, the absence of a DWORF antibody for histological investigations does currently not allow us to investigate the presence of DWORF in these S/ER clusters. Despite strong reduction in PLN S/ER cluster formations, cells with clusters still develop and were also observed in 7-week-old and 18-week-old R14Δ/ΔDWORFTg mice. This reduced rate of detrimental cluster formation can explain the strongly delayed deterioration of cardiac function of R14Δ/ΔDWORFTg mice overtime (Figure S14).
Studies with the PLN-R14del pathogenic variant have repeatedly shown altered calcium handling properties, but the exact effects and mechanisms remain unclear 4–7,10,13,36. Here we described enhanced calcium re-uptake in cardiomyocytes isolated from R14Δ/Δ mice, which is in line with several other publications on altered calcium re-uptake by mutant PLN-R14del 6–8,36. Likewise, calcium S/ER re-uptake is accelerated in PLN−/− (knockout) mice, but in contrast to R14Δ/Δ mice, PLN knockout mice do not develop HF 37,38. Thus, the p.Arg14del pathogenic variant may behave as a loss-of-function mutation in calcium handling, but this cannot explain disease development in R14Δ/Δ mice. Since calcium re-uptake was already enhanced in R14Δ/Δ cardiomyocytes, DWORF overexpression did not result in an additional increase in calcium re-uptake in R14Δ/ΔDWORFTg cardiomyocytes. Hence, improving calcium S/ER re-uptake appears to be ineffective in PLN-R14del cardiomyopathy. Therefore, in contrast to the protective effects of DWORF in other heart failure models 14,17,39, its protective effect in PLN-R14del cardiomyopathy does not appear to be related to calcium handling. Based on the data presented above we therefore consider it more likely that the protective effect of DWORF involves the prevention of abnormal S/ER cluster formation in PLN-R14del cardiomyopathy.
A limitation of this study is that we did not use a heterozygous PLN-R14del mouse model (R14+/Δ), that would resemble the same genetic situation as human carriers with one normal and one pathogenic allele. Instead, we used a homozygous PLN-R14del mouse model (R14Δ/Δ) that shows similar characteristics as the R14+/Δ mice and human patients but has the advantage of accelerated disease development. In addition to previously published data, we confirmed that the R14+/Δ mouse model is a mild disease variant with regard to calcium handling and sarcomere function. Relaxation is also accelerated in adult cardiomyocytes from R14+/Δ mice, with relaxation time and velocity values intermediate of R14Δ/Δ and WT mice (Figure S15). Moreover, our finding that perinuclear PLN structures are composed of disorganized S/ER in homozygous mice was confirmed in PLN-R14del patient tissue, which further validates the translatability of this mouse model. The strategy of increasing the DWORF level to delay disease progression could be even more effective in human patients compared to the effects observed in the current study in homozygous mice, considering that disease progression is milder due to the presence of WT PLN in patients.
In summary, PLN-R14del induced perinuclear clustering of PLN and S/ER structural deformations trigger cardiomyocyte dysfunction. This causes cardiomyocyte cell loss as indicated by elevated troponin levels, explaining the excessive fibrosis, which finally culminates in severe cardiac dysfunction and death (Figure 8). Whether other PLN pathogenic variants also cause structural S/ER alterations is not known but deserves future attention. Importantly, DWORF can diminish PLN-R14del-induced S/ER cluster formation and significantly extend life span in an established mouse model for PLN-R14del cardiomyopathy (Figure 8).
To conclude, we reveal that the characteristic PLN clusters present in the PLN-R14del mouse model and human patients are comprised of disorganized perinuclear S/ER and argue that aberrant S/ER formation is the key mechanism in the development of PLN-R14del cardiomyopathy. Preventing structural S/ER alterations by DWORF overexpression or by other interventions could be a promising therapeutic strategy in this disease.
Supplementary Material
CIRCULATION RESEARCH.
Novelty and Significance
What is known?
The p.Arg14del variant of the phospholamban (PLN) gene causes cardiomyopathy, leading to severe heart failure (HF), which cannot be properly treated using current HF therapies.
Mechanistic insights in disease development are required for a specific treatment and a causal role in disease development has been suggested for clustered perinuclear PLN protein.
DWORF (dwarf open reading frame) is a SERCA (sarco/endoplasmic reticulum Ca2+ ATPase) activator, with a function opposite to PLN and has shown to be cardioprotective in several murine HF models.
What New Information Does This Article Contribute?
The current work shows that the characteristic dense perinuclear PLN structures in the PLN-R14del mouse model and human patients are composed of strongly clustered and disorganized cardiac sarco/endoplasmic reticulum (S/ER).
DWORF overexpression delays cardiac dysfunction and extends life span in a PLN-R14del cardiomyopathy mouse model.
DWORF exerts its positive effects in PLN-R14del cardiomyopathy via the reduction of perinuclear PLN clustering and associated toxic S/ER disorganization, not via a change in SR calcium re-uptake.
These data support S/ER disorganization as a detrimental mechanism in the development of PLN-R14del cardiomyopathy. Preventing structural S/ER alterations by DWORF overexpression or by other interventions could be a promising therapeutic strategy in this disease.
Acknowledgements
We would like to thank Sietske-Nyncke Zijlstra and Martin M. Dokter for their excellent technical assistance with, amongst others, the calcium contraction assays performed on isolated adult mouse cardiomyocytes and histological analyses. Moreover, we are grateful for the human patient tissues that have been retrieved from the UMCG Pathology Biobank and we would like to thank animal caretakers and staff from UMCG central animal facility (CDP) for their services.
Sources of Funding
This work was supported by a grant from the Netherlands Heart Foundation [CVON PREDICT2, grant 2018–30]; the Leducq Foundation (Cure PhosphoLambaN induced Cardiomyopathy, Cure-PLaN); the Ubbo Emmius Foundation; grants from the Netherlands Heart Institute (NLHI); the PLN foundation; the European Research Council [ERC CoG 818715, SECRETE-HF to R.A.d.B]; the National Institutes of Health (NIH) grants [HL130253 to R.B.-D and E.N.O., HL141630 to C.A.M.]; Leducq Foundation Transatlantic Network of Excellence (20CVD04 to E.N.O.); ZonMW grant [91111.006 to B.N.G.G.]; the Netherlands Electron Microscopy Infrastructure (NEMI) to B.N.G.G.; and the Nederlandse Organisatie voor Wetenschappelijk Onderzoek grant [NWO National Roadmap for Large-Scale Research Infrastructure of the Dutch Research Council, 184.034.014 to B.N.G.G.]. Part of the work has been performed in the UMCG Microscopy and Imaging Center (UMIC), sponsored by the Dutch Research Council NWO 175-010-2009-023 and NRGWI.obrug.005.
Disclosures
The UMCG, which employs several of the authors, has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. R.A.d.B. received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche.
Non-standard Abbreviations and Acronyms:
- ATL3
atlastin-3
- DWORF
dwarf open reading frame
- EM
electron microscopy
- HRC
histidine-rich calcium binding protein
- IF
immunofluorescent
- PLN
phospholamban
- R14Δ/Δ
homozygous PLN-R14del mice
- R14Δ/ΔDWORFTg
R14Δ/Δ mice carrying the DWORF transgene
- S/ER
sarco/endoplasmic reticulum
- SERCA
sarco/endoplasmic reticulum Ca2+ ATPase
- WT
Wildtype; transgene-negative
References
- 1.Van Der Zwaag PA, Van Rijsingen IAW, Asimaki A, Jongbloed JDH, Van Veldhuisen DJ, Wiesfeld ACP, Cox MGPJ, Van Lochem LT, De Boer RA, Hofstra RMW, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: Evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 2012;14:1199–207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Hof IE, van der Heijden JF, Kranias EG, Sanoudou D, de Boer RA, van Tintelen JP, van der Zwaag PA, Doevendans PA. Prevalence and cardiac phenotype of patients with a phospholamban mutation. Netherlands Hear. J. 2019;27:64–69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.MacLennan DH, Kranias EG. Phospholamban: A crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 2003;4:566–77. [DOI] [PubMed] [Google Scholar]
- 4.Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, Parekh RR, Dorn GW, et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 2006;103:1388–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kumar M, Haghighi K, Koch S, Rubinstein J, Stillitano F, Hajjar RJ, Kranias EG, Sadayappan S. Myofilament Alterations Associated with Human R14del-Phospholamban Cardiomyopathy. Int. J. Mol. Sci. 2023;24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Ceholski DK, Trieber CA, Young HS. Hydrophobic imbalance in the cytoplasmic domain of phospholamban is a determinant for lethal dilated cardiomyopathy. J. Biol. Chem. 2012;287:16521–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Badone B, Ronchi C, Lodola F, Knaust AE, Hansen A, Eschenhagen T, Zaza A. Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Int. J. Mol. Sci. 2021;22:13500. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Haghighi K, Pritchard T, Bossuyt J, Waggoner JR, Yuan Q, Fan GC, Osinska H, Anjak A, Rubinstein J, Robbins J, et al. The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase. J. Mol. Cell. Cardiol. 2012; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Wu AZ, Xu D, Yang N, Lin SF, Chen PS, Cala SE, Chen Z. Phospholamban is concentrated in the nuclear envelope of cardiomyocytes and involved in perinuclear/nuclear calcium handling. J. Mol. Cell. Cardiol. 2016;100:1–8. [DOI] [PubMed] [Google Scholar]
- 10.Cuello F, Knaust AE, Saleem U, Loos M, Raabe J, Mosqueira D, Laufer S, Schweizer M, Kraak P, Flenner F, et al. Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation. EMBO Mol. Med. 2021;13:e13074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.te Rijdt WP, van Tintelen JP, Vink A, van der Wal AC, de Boer RA, van den Berg MP, Suurmeijer AJH. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology. 2016;69:542–50. [DOI] [PubMed] [Google Scholar]
- 12.Eijgenraam TR, Boukens BJ, Boogerd CJ, Schouten EM, van de Kolk CWA, Stege NM, te Rijdt WP, Hoorntje ET, van der Zwaag PA, van Rooij E, et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Sci. Rep. 2020;10:9819. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Eijgenraam TR, Boogerd CJ, Stege NM, Oliveira Nunes Teixeira V, Dokter MM, Schmidt LE, Yin X, Theofilatos K, Mayr M, van der Meer P, et al. Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy. Circ. Heart Fail. 2021;14:e008532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Nelson BR, Makarewich CA, Anderson DM, Winders BR, Troupes CD, Wu F, Reese AL, McAnally JR, Chen X, Kavalali ET, et al. Muscle physiology: A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science. 2016;351:271–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Fisher MlE, Bovo E, Cho EE, Pribadi MP, Dalton MP, Lemieux MJ, Rathod N, Aguayo-Ortiz R, Espinoza-Fonseca LM, Robia SL, et al. Dwarf open reading frame (DWORF) peptide is a direct activator of the sarcoplasmic reticulum calcium pump SERCA. bioRxiv. 2020;10:e65545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Li A, Yuen SL, Stroik DR, Kleinboehl E, Cornea RL, Thomas DD. The transmembrane peptide DWORF activates SERCA2a via dual mechanisms. J. Biol. Chem. 2021;296:100412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Makarewich CA, Munir AZ, Schiattarella GG, Bezprozvannaya S, Raguimova ON, Cho EE, Vidal AH, Robia SL, Bassel-Duby R, Olson EN. The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy. Elife. 2018;7:e38319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Makarewich CA, Bezprozvannaya S, Gibson AM, Bassel-Duby R, Olson EN. Gene therapy with the DWORF micropeptide attenuates cardiomyopathy in mice. Circ. Res. 2020;127:1340–1342. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Du W, Piek A, Marloes Schouten E, van de Kolk CWA, Mueller C, Mebazaa A, Voors AA, de Boer RA, Silljé HHW. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics. 2018; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.du Sert NP, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18:e3000410. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Withaar C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, Silljé HHW, Schouten EM, Dokter MM, Voors AA, Westenbrink BD, Lam CSP, et al. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovasc. Res. 2021;117:2108–2124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zacchigna S, Paldino A, Falcão-Pires I, Daskalopoulos EP, Dal Ferro M, Vodret S, Lesizza P, Cannatà A, Miranda-Silva D, Lourenço AP, et al. Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: A position paper of the ESC Working Group on Myocardial Function. Cardiovasc. Res. 2021;117:43–59. [DOI] [PubMed] [Google Scholar]
- 23.Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 2012;9:671–675. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ackers-Johnson M, Li PY, Holmes AP, O’Brien SM, Pavlovic D, Foo RS. A Simplified, Langendorff-Free Method for Concomitant Isolation of Viable Cardiac Myocytes and Nonmyocytes from the Adult Mouse Heart. Circ. Res. 2016;119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.de Boer P, Pirozzi NM, Wolters AHG, Kuipers J, Kusmartseva I, Atkinson MA, Campbell-Thompson M, Giepmans BNG. Large-scale electron microscopy database for human type 1 diabetes. Nat. Commun. 2020;11:2475. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Kuipers J, de Boer P, Giepmans BNG. Scanning EM of non-heavy metal stained biosamples: Large-field of view, high contrast and highly efficient immunolabeling. Exp. Cell Res. 2015;337:202–207. [DOI] [PubMed] [Google Scholar]
- 27.Sikkel MB, Francis DP, Howard J, Gordon F, Rowlands C, Peters NS, Lyon AR, Harding SE, Macleod KT. Hierarchical statistical techniques are necessary to draw reliable conclusions from analysis of isolated cardiomyocyte studies. Cardiovasc. Res. 2017;113:1743–1752. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Grote Beverborg N, Später D, Knöll R, Hidalgo A, Yeh ST, Elbeck Z, Silljé HHW, Eijgenraam TR, Siga H, Zurek M, et al. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. Nat. Commun. 2021;12:5180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.te Rijdt WP, van der Klooster ZJ, Hoorntje ET, Jongbloed JDH, van der Zwaag PA, Asselbergs FW, Dooijes D, de Boer RA, van Tintelen JP, van den Berg MP, et al. Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovasc. Pathol. 2017;30:23–26. [DOI] [PubMed] [Google Scholar]
- 30.Eijgenraam TR, Silljé HHW, de Boer RA. Current understanding of fibrosis in genetic cardiomyopathies. Trends Cardiovasc. Med. 2020; [DOI] [PubMed] [Google Scholar]
- 31.Nickel AG, Von Hardenberg A, Hohl M, Löffler JR, Kohlhaas M, Becker J, Reil JC, Kazakov A, Bonnekoh J, Stadelmaier M, et al. Reversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure. Cell Metab. 2015;22:472–484. [DOI] [PubMed] [Google Scholar]
- 32.Piek A, de Boer RA, Silljé HHW. The fibrosis-cell death axis in heart failure. Heart Fail. Rev. 2016;21:199–211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Te Rijdt WP, Ten Sande JN, Gorter TM, Van Der Zwaag PA, Van Rijsingen IA, Boekholdt SM, Van Tintelen JP, Van Haelst PL, Planken RN, De Boer RA, et al. Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. Eur. Hear. journal. Cardiovasc. Imaging. 2019;20:92–100. [DOI] [PubMed] [Google Scholar]
- 34.Rustad MD, Roopnarine O, Cornea RL, Thomas DD. Interaction of DWORF with SERCA and PLB as determined by EPR spectroscopy. Biochem. Biophys. Res. Commun. 2023;645:97–102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Schiemann R, Buhr A, Cordes E, Walter S, Heinisch JJ, Ferrero P, Milting H, Paululat A, Meyer H. Neprilysins regulate muscle contraction and heart function via cleavage of SERCA-inhibitory micropeptides. Nat. Commun. 2022;13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Hughes E, Middleton DA. Comparison of the structure and function of phospholamban and the arginine-14 deficient mutant associated with dilated cardiomyopathy. PLoS One. 2014;9:e106746. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, Kranias EG. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. 1994;75:401–409. [DOI] [PubMed] [Google Scholar]
- 38.Slack JP, Grupp IL, Dash R, Holder D, Schmidt A, Gerst MJ, Tamura T, Tilgmann C, James PF, Johnson R, et al. The enhanced contractility of the phospholamban-deficient mouse heart persists with aging. J. Mol. Cell. Cardiol. 2001;33:1031–1040. [DOI] [PubMed] [Google Scholar]
- 39.Morales ED, Yue Y, Watkins TB, Han J, Pan X, Gibson AM, Hu B, Brito-Estrada O, Yao G, Makarewich CA, et al. Dwarf Open Reading Frame (DWORF) Gene Therapy Ameliorated Duchenne Muscular Dystrophy Cardiomyopathy in Aged mdx Mice. J. Am. Heart Assoc. 2023;12. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data, methods, and study materials used to conduct the research are available from the corresponding authors on reasonable request. Expanded Methods are available in the Supplemental Material, also please see the Major Resources Table in the Supplemental Materials.